CONgenital Cytomegalovirus: Efficacy of antiviral treatment in a non-Randomized Trial with historical control group CONgenitaal Cytomegalovirus.
Phase of Trial: Phase III
Latest Information Update: 07 Jun 2017
Price : $35 *
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections; Hearing loss
- Focus Therapeutic Use
- Acronyms CONCERT-2
- 20 Jun 2015 Planned End Date changed from 1 Jan 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
- 20 Jun 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Oct 2016 as reported by ClinicalTrials.gov record.
- 06 Dec 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT02005822).